News

The FDA plans to conduct a speedy review of the supplemental new drug application for ivosidenib tablets as treatment of IDH1-positive, relapsed or refractory myelodysplastic syndrome.

According to Erica Mayer, MD, MPH, an analysis of the PALLAS study that patients with a higher BMI appeared to have less toxicity from the CDK4/6 inhibitor, palbociclib, and fewer cases of early discontinuation due to toxicity.

The first liver-directed therapy for the treatment of adult with metastatic uveal melanoma is now FDA approved.

Prior suspicions about a patient death in iMMagine-1 had been cleared up and the trial will continue with the permission of the FDA.

During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived.

In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study.

Findings from 2 cohorts of the phase 3 MagnetisMM-3 trial led to the FDA approval of elranatamab-bcmm for relapsed or refractory multiple myeloma treatment.

An era of advanced molecular testing and personalized medicine has allowed for the de-escalation of breast cancer treatment for many patients. This is part 1 of a 2-part series on overtreatment of breast cancer.

Based on the largest clinical trial of patients with HER2-amplified biliary tract cancer, a novel anti-HER bispecific antibody may be the next option.

Investigators have shared final results from the first prospective study of a BRAK/MEK inhibitor combination in patients with advanced rare cancer, including anaplastic thyroid cancer.

Patients with hormone receptor-positive endometrial cancer had an objective response rate of 30%, including 8 confirmed responses, when treated with letrozole with abemaciclib.

Results from the phase 3 MAGNITUDE study have led to a quick FDA decision on the future of a dual action tablet for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer.

Samer A. Srour, MD, MS, discusses what challenges need to be faced when moving forward with the phase 1 trial of Orca-Q in patients undergoing haploidentical allogeneic hematopoietic stem cell transplantation.

A phase 1/2 study marks the beginning of Genprex, Inc's clinical development of quratusugene ozeplasmid in small cell lung cancer.

Nathan Bahary, MD, PhD, discusses the ongoing challenge of chemotherapy drug shortages in the oncology field.

Various combination strategies are being explored in soft tissue sarcomas in efforts to increase efficacy.

Aaron T. Gerds, MD, MS, discusses the 48-week results of the MOMENTUM trial and where momelotinib goes from here in the treatment of patients with myelofibrosis.

As the first study of its kind, KEYNOTE-B61 has demonstrated potential to move pembrolizumab plus lenvatinib earlier in the treatment of non-clear cell renal cell carcinoma.

Data from the phase 2 MonumenTAL-1 study support the accelerated approval of talquetamab in patients with relapsed/refractory who have received at least 4 prior lines of therapy.

Findings from a study published in JAMA Oncology showed no survival difference in fixed duration immune checkpoint inhibitor group vs the indefinite-duration group among patients with non–small cell lung cancer

The FDA has approved avasopasem for patients with head and neck cancer to treat their radiotherapy-induced severe oral mucositis.

In an interview with Targeted Oncology, Hun Ju Lee, MD, discussed the encouraging responses shown with the combination of zilovertamab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia, and highlighted other studies making headway in the field.

Approval of pralsetinib for the treatment of RET fusion-positive non–small cell lung cancer in based on positive results from the phase 1/2 ARROW trial.

Raajit K. Rampal, MD, PhD, discusses the evolution of treatments for patients with myelofibrosis, and notes what he is excited to see more of in the future.

Early clinical trial in gastrointestinal and brain cancers aim to better understand the safety and efficacy of CEND-1-targeted therapy and develop a novel CEND-1 agent.

A positive association with progression-free survival in patients with advanced non–small cell lung cancer who were treated with first-line pembrolizumab was observed using a multiomics approach.

Lisaftoclax is a novel, orally administered small-molecule BCL-2 selective inhibitor. A study of the agent in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma will commence in the second half of 2023.

After more than 2 years without, the FDA has approved a companion diagnostic to identity candidates for treatment with avapritinib.

The phase 2b VIRAGE study evaluating the combination of VCN-01 with standard-of-care chemotherapy in patients with pancreatic cancer remains on track to be fully-enrolled in the first quarter of 2024.

Since blinatumomab was first approved in 2014 for relapsed/refractory acute lymphoblastic leukemia, the field has seen rapid progress. Now, a growing number of BiTEs are under development for different solid tumors and hematologic malignancies.